Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDeltex Medical Regulatory News (DEMG)

Share Price Information for Deltex Medical (DEMG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.1025
Bid: 0.10
Ask: 0.105
Change: 0.00 (0.00%)
Spread: 0.005 (5.00%)
Open: 0.1025
High: 0.1025
Low: 0.1025
Prev. Close: 0.1025
DEMG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results from head to head trial presented

11 Jul 2016 07:00

RNS Number : 7475D
Deltex Medical Group PLC
11 July 2016
 

11 July 2016

 

Deltex Medical Group plc

("Deltex Medical", "Deltex" or "the Company")

 

Results from head to head trial presented

Significantly better outcomes from ODM

 

Deltex Medical Group plc (LSE-AIM: DEMG), the global leader in oesophageal Doppler monitoring ("ODM"), today announces initial results from the first randomised controlled trial to compare post-operative outcomes when using ODM to the most commonly used alternative technology.

 

Doctors from St Thomas' Hospital, London, presented the findings from their study of 127 patients at the annual meeting of The Association of Coloproctology of Great Britain and Ireland. All patients were undergoing bowel surgery, 40% of them using laparoscopic ('keyhole') techniques, within a well established enhanced recovery programme. Each was monitored with both CardioQ-ODM and an uncalibrated Pulse Pressure Waveform Analysis ("PPWA") monitor which was originally developed at St Thomas' Hospital for intensive care use about 25 years ago: in half the patients care was guided using ODM and in the other half using PPWA.

 

Statistically significant results included:

 

· "Poor agreement": the PPWA device prompted a different intervention to that indicated by ODM two times in every five, resulting in either too much or too little fluid being given at that time

· 50% more PPWA patients required treatment with vaso-active drugs

· ODM patients were able to get out of bed and move around on average one day sooner

· ODM patients went home on average two days earlier (six days compared to eight days)

 

Prior to these results, there have been 13 studies using ODM during surgery with positive outcomes (i.e. either a statistically significant reduction in complications or length of stay or both) and eight trials using this particular PPWA device during surgery but no positive outcomes.

 

Ewan Phillips, Deltex Medical's Chief Executive, commented:

 

"These results confirm both the superiority of ODM over PPWA and that intra-operative fluid management, done properly, has a crucial role in determining optimal patient outcomes in modern enhanced recovery programmes incuding laparoscopic surgical techniques.

 

"This is the second important new trial to be presented since we launched our new, easier to use, TruFlow probes in May. The first trial from Spain, the largest ever randomised controlled trial of ODM, showed significant reductions in both post-operative complications and length of hospital stay and this second study shows why all the key evidence in this field comes from use of ODM."

 

For further information, please contact:-

 

Deltex Medical Group plc

01243 774 837

investorinfo@deltexmedical.com

Nigel Keen, Chairman

Ewan Phillips, Chief Executive

Jonathan Shaw, Group Finance Director

Barry Curtis, Company Secretary

Nominated Adviser & Broker

Arden Partners plc

020 7614 5900

Chris Hardie

 

Financial Public Relations

IFC Advisory

0203 053 8671

Tim Metcalfe

Graham Herring

Heather Armstrong

 

Notes for Editors

 

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

 

Company goal

ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.

 

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

 

There are over 3,200 monitors installed in hospitals around the world and over 650,000 patients have been treated to date using Deltex Medical's single patient disposable probes.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEAFXEFAXKEAF
Date   Source Headline
28th Mar 20247:00 amRNSResults for the year ended 31 December 2023
2nd Feb 20245:11 pmRNSHolding(s) in Company
31st Jan 20245:00 pmRNSTotal Voting Rights
18th Jan 20245:01 pmRNSIssue of Equity
18th Jan 20247:00 amRNSYear-end trading update
4th Dec 20237:00 amRNSCommercial update, board changes & new auditor
18th Sep 20237:00 amRNSInterim results to 30 June 2023
31st Aug 20235:00 pmRNSTotal Voting Rights
2nd Aug 20236:23 pmRNSHolding(s) in Company
2nd Aug 20235:32 pmRNSHolding(s) in Company
2nd Aug 20238:00 amRNSFundraising completion, trading restoration & TVR
2nd Aug 20237:30 amRNSRestoration - Deltex Medical Group PLC
1st Aug 202310:04 amRNSResult of General Meeting
24th Jul 20237:00 amRNSResult of Retail Offer
18th Jul 20234:47 pmRNSExtension of Retail Offer Closing Time
14th Jul 20236:03 pmRNSRetail offer to raise up to £500,000
14th Jul 20236:01 pmRNSPlacing, Subscription and Retail Offer
10th Jul 20237:00 amRNSRelease of new next generation TrueVue System
6th Jul 20237:13 amRNSHalf-year Trading Update & Potential Fundraise
26th Jun 20237:30 amRNSSuspension - Deltex Medical Group PLC
26th Jun 20237:00 amRNSTrading update and suspension of trading on AIM
19th May 20231:35 pmRNSHolding(s) in Company
17th May 20233:24 pmRNSResult of AGM
17th May 20237:00 amRNSChairman’s Statement to the Annual General Meeting
28th Apr 20235:00 pmRNSTotal Voting Rights
25th Apr 20237:00 amRNSNew monitor launch update & new loan facility
11th Apr 20235:43 pmRNSIssue of Equity
30th Mar 20237:00 amRNSResults for the year ended 31 December 2022
27th Feb 20237:00 amRNSConvertible loan notes repayment date extension
24th Jan 20237:00 amRNSYear end trading update
22nd Dec 20227:00 amRNSYear end update
20th Sep 20227:00 amRNSInterim Results
14th Jul 20227:00 amRNSCompletion of Nominated Adviser due diligence
7th Jul 20227:00 amRNSHalf year trading update
18th May 20223:41 pmRNSResult of AGM
18th May 20227:00 amRNSChairman's Statement to Annual General Meeting
28th Apr 20227:00 amRNSChange of Adviser
7th Apr 20227:00 amRNSResults for the year ended 31 December 2021
2nd Mar 20224:30 pmRNSHolding(s) in Company
17th Feb 20224:02 pmRNSGrant of options
8th Feb 20227:00 amRNSSubscription and extension of Debt Facility
26th Jan 20227:00 amRNSContract win in the Americas
12th Jan 20227:00 amRNSIssue of Equity
11th Jan 20227:00 amRNSPre-close statement
20th Dec 20217:00 amRNSSuccessful Innovate UK Smart Award
20th Sep 20217:00 amRNSInterim results to 30 June 2021
22nd Jul 20213:48 pmRNSIssue of Equity
16th Jul 20217:00 amRNSIssue of Equity
8th Jul 20217:00 amRNSPre-close trading update
30th Jun 20212:06 pmRNSPosting of Accounts

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.